A unanimous ruling from the 5th U.S. Circuit Court of Appeals in New Orleans has blocked the mailing of mifepristone prescriptions, requiring the abortion pill to be dispensed only in person at clinics. The decision, issued Friday, overrules regulations set by the Food and Drug Administration and affects all 50 states, including those with no abortion restrictions.
The ruling came after Louisiana Attorney General Liz Murrill sued the FDA last month, arguing that its telehealth and mail distribution rules allowed out-of-state prescribers to bypass Louisiana’s near-total abortion ban. Judge Kyle Duncan, appointed by President Donald Trump, wrote that the federal regulations created a pathway for the drug to reach Louisiana residents in direct conflict with state law.
FDA officials have said the agency is currently conducting a new review of mifepristone’s safety, but the court noted no timeline had been set for its completion.
Mifepristone and how it is used
Mifepristone was approved by the FDA in 2000 as a safe and effective method for ending early pregnancies. It is typically used alongside a second drug, misoprostol, which is less effective on its own and was not affected by Friday’s ruling. Medication abortions now account for more than half of all abortions in the United States, and roughly one in four are prescribed through telehealth.
Abortion rights advocates have pointed to telehealth access as a major reason the national abortion rate did not drop significantly after Roe v. Wade was overturned in 2022. That dynamic has made mifepristone prescriptions, and the providers who issue them remotely, central targets for abortion opponents in the years since.
The Supreme Court appeal
Within a day of the ruling, Danco Laboratories, the manufacturer of mifepristone and a defendant in the case, filed an emergency request asking the U.S. Supreme Court to block the 5th Circuit decision while appeals continue. Because mifepristone is Danco’s only product, the company argued that a nationwide restriction on mail and telehealth distribution would cause irreparable harm to its operations.
The filing described the ruling as unprecedented, noting that no federal court had previously overruled FDA scientific regulations at the request of a single state. Legal experts agreed the case breaks new ground in the relationship between federal drug regulation and state abortion law.
The FDA and the Department of Justice did not immediately respond to requests for comment on the ruling.
What this means for patients and providers
Some Democratic-led states have enacted shield laws intended to protect telehealth providers who prescribe and mail abortion pills to patients in states with bans. Those laws are now being tested in civil and criminal proceedings in Louisiana and Texas, and Friday’s ruling adds new pressure to that legal framework.
Providers in shield law states say they intend to continue serving patients in all 50 states while working with legal counsel to understand the full scope of the ruling’s impact.
Legal experts described the decision as one of the most significant shifts in abortion access since Roe was overturned. The ruling affects women in states with no abortion restrictions just as much as those in states with strict bans, because it eliminates mail delivery of the pill regardless of local law.
Mifepristone fight and the midterm elections
The ruling arrives roughly six months before the 2026 midterm elections, and abortion policy is expected to return as a galvanizing issue for voters. Since Roe fell, abortion has appeared on the ballot directly in 17 states, with voters siding with abortion rights in 14 of those contests.
Trump drew criticism from some anti-abortion allies who felt he should have moved to restrict mifepristone access himself rather than leaving it to the courts. Others in the anti-abortion movement celebrated the ruling as a major victory while pushing for further federal action.
Abortion rights groups called the decision deeply out of step with public opinion and the scientific record, and said they would continue fighting the ruling through every available legal channel.
The Supreme Court is expected to decide whether to grant an emergency stay in the coming days. Its response will determine whether the 5th Circuit’s ruling remains in effect while the broader legal battle plays out.
